or Try an Advanced Search...

    Cancer Therapies Stocks List

    Symbol Grade Name % Change
    GTBP C GT Biopharma, Inc. -0.60
    AVBP C ArriVent BioPharma, Inc. -2.39
    IKNA C Ikena Oncology, Inc. 0.88
    ANL D Adlai Nortye Ltd. 1.16
    PSNL D Personalis, Inc. -2.17
    APRE D Aprea Therapeutics, Inc. -2.90
    POAI D Predictive Oncology Inc. 3.89
    SNDX F Syndax Pharmaceuticals, Inc. -1.97
    BYSI F BeyondSpring, Inc. 0.00
    IOBT F IO Biotech, Inc. -15.37
    View As Page of Charts
    Related Industries: Biotechnology Medical Instruments & Supplies
    Related Stock Lists: Cancer Biopharmaceutical Biotechnology Antineoplastic Drugs Clinical Medicine Solid Tumors Tumor Anti Cancer Therapies Biology Cancer Cell Cancer Treatment Genomics Immune System Life Sciences Lung Cancer Medicine NSCLC Oncology Pharmaceutical Acute Myeloid Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Cancer Therapies stocks.

    Symbol Grade Name Weight
    ARKG F ARK Genomic Revolution Multi-Sector ETF 2.7
    SURI C Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 1.47
    CNCR F Loncar Cancer Immunotherapy ETF 1.34
    SBIO C ALPS Medical Breakthroughs ETF 0.93
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.66
    View all Cancer Therapies ETFs...
    Compare ETFs
    Compare ARKG to BBC Compare ARKG to SURI Compare SURI to CNCR

        Cancer Therapies Stocks Recent News

        Date Stock Title
        Nov 18 SNDX Syndax secures FDA OK for new kind of leukemia drug
        Nov 18 SNDX FDA approves Syndax’s Revuforj to treat leukaemia
        Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
        Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
        Nov 15 POAI Predictive Oncology Third Quarter 2024 Earnings: Misses Expectations
        Nov 15 GTBP GT Biopharma GAAP EPS of -$1.53
        Nov 15 AVBP ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
        Related Industries: Biotechnology Medical Instruments & Supplies
        Related Stock Lists: Cancer Biopharmaceutical Biotechnology Antineoplastic Drugs Clinical Medicine Solid Tumors Tumor Anti Cancer Therapies Biology Cancer Cell Cancer Treatment Genomics Immune System Life Sciences Lung Cancer Medicine NSCLC Oncology Pharmaceutical Acute Myeloid Leukemia
        Cancer Therapies

        Cancer therapies are treatments used to destroy or control cancer cells. These therapies can include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Depending on the type and stage of cancer, a combination of therapies may be used.

        Browse All Tags